Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 17/20 | 0.60 |
| ▸ | GRM5 | P41594 | 7/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopropane SCHEMBL28516873 | 0.98 | MAOB (0.59) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL1570340 | 0.91 | MAOB (0.75) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL10334859 | 0.90 | MAOB (0.52) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL31279913 | 0.90 | MAOB (0.52) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL17261613 | 0.89 | MAOB (0.53) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL5473517 | 0.88 | MAOB (0.53) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL769313 | 0.87 | NPC1 (0.54) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL19278336 | 0.84 | APP (0.50) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL14162499 | 0.83 | MAOB (0.64) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL20761773 | 0.83 | MAOB (0.48) | MAOBGRM5NPC1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111518117-B | 1, 2-oxazinopyran compound and preparation method and application thereof | 西安凯新生物科技有限公司 | 2022-08-26 | — | — | CN | claimed |
| CN-111518117-A | 1, 2-oxazinopyran compound and preparation method and application thereof | 朱翠萍 | 2020-08-11 | — | — | CN | claimed |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4598928-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250129076-A1 | FUSED TETRACYCLIC COMPOUNDS, COMPOSITIONS AND DIAGNOSTIC APPLICATIONS THEREOF | BENAZIR FATHIMA (IN) | 2025-04-24 | — | — | US | disclosed |
| US-20250122152-A1 | KAT6 Inhibitors | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-17 | — | — | US | disclosed |
| WO-2025068943-A1 | KAT6 INHIBITORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024140431-A1 | COMPOUNDS COMPRISING HETEROARYL RINGS AND COMPOSITIONS AND METHODS THEREOF | IONGEN THERAPEUTICS CO., LTD. (CN) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024077006-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2023017548-A1 | FUSED TETRACYCLIC COMPOUNDS, COMPOSITIONS AND DIAGNOSTIC APPLICATIONS THEREOF | BENAZIR J DR FATHIMA (IN) | 2023-02-16 | — | — | WO | disclosed |
| CN-111518117-B | 1, 2-oxazinopyran compound and preparation method and application thereof | 西安凯新生物科技有限公司 | 2022-08-26 | — | — | CN | disclosed |
| EP-0325964-A1 | Aminomethyl-chroman and -thiochroman compounds | ABBOTT LABORATORIES (US) | 1989-08-02 | — | — | EP | disclosed |
| WO-1989006534-A1 | AMINOMETHYL-CHROMAN AND -THIOCHROMAN COMPOUNDS | ABBOTT LABORATORIES (US) | 1989-07-27 | — | — | WO | disclosed |
| EP-0313295-A2 | Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases | PFIZER INC. (US) | 1989-04-26 | — | — | EP | disclosed |
| US-4530919-A | A 1,2,3,4-tetrahydronaphthalene carboxylic acid | PFIZER INC. (US) | 1985-07-23 | — | — | US | disclosed |
| US-4374148-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1983-02-15 | — | — | US | disclosed |
| US-4305955-A | ORAL HYPOGLYCEMIC AGENTS, CHROMAN-4-CARBOXYLIC ACID OR THIOCHROMAN-4-CARBOXYLIC ACID | PFIZER INC. (US) | 1981-12-15 | — | — | US | disclosed |
| US-4261988-A | ANTICHOLESTEROL AGENTS USED IN ANIMAL HUSBANDRY | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-14 | — | — | US | disclosed |
| US-4238606-A | ANTIALLERGANS | FISONS LIMITED (GB) | 1980-12-09 | — | — | US | disclosed |
| US-4159273-A | ANTIALLERGENS, ANTIHISTAMINES | FISONS LIMITED (GB) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129076-A1 | FUSED TETRACYCLIC COMPOUNDS, COMPOSITIONS AND DIAGNOSTIC APPLICATIONS THEREOF | POLRMT, POLM, DNTT | MAOB 2203/4885GRM5 4762/4885NPC1 544/4885 |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | MAOB 2905/4885GRM5 1818/4885NPC1 783/4885 |
| US-20250122152-A1 | KAT6 Inhibitors | KAT6A, KAT6B, KAT7 | MAOB 1231/4885GRM5 2305/4885NPC1 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.